$1.34
+0.10 (+8.06%)
Open$1.25
Previous Close$1.24
Day High$1.34
Day Low$1.24
52W High$1.88
52W Low$0.81
Volume—
Avg Volume426.9K
Market Cap71.99M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+419.4% upside
Current
$1.34
$1.34
Target
$6.96
$6.96
$5.52
$6.96 avg
$10.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.44M | 13.53M | 15.01M |
| Net Income | -947,825 | -765,390 | -987,033 |
| Profit Margin | -6.6% | -5.7% | -6.6% |
| EBITDA | -1,267,375 | -1,123,871 | -1,333,015 |
| Free Cash Flow | -656,212 | -624,188 | -715,122 |
| Rev Growth | +21.5% | +1.8% | +6.7% |
| Debt/Equity | 0.93 | 0.92 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |